<DOC>
	<DOCNO>NCT00052936</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Monoclonal antibody rituximab locate tumor cell either kill deliver tumor-killing substance without harm normal cell . It yet know whether combination chemotherapy effective without rituximab treat aggressive non-Hodgkin 's lymphoma . PURPOSE : This randomized phase III trial study well give cyclophosphamide , doxorubicin , vincristine , prednisone together without rituximab work treat old patient aggressive non-Hodgkin 's lymphoma . ( This trial long randomize 6/2005 ) .</brief_summary>
	<brief_title>Combination Chemotherapy With Without Rituximab Treating Older Patients With Non-Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare efficacy cyclophosphamide , doxorubicin , vincristine , prednisone ( CHOP ) v without rituximab elderly patient aggressive non-Hodgkin 's lymphoma . - Compare efficacy 6 v 8 course CHOP chemotherapy patient treat regimen . - Compare rate complete remission , rate primary progression , tumor control , disease-free survival , overall survival , relapse radiotherapy patient treat regimen . - Compare safety side effect regimens patient . Secondary - Compare short-term long-term side effect regimens patient . - Compare quality life patient treat regimen . - Compare cost regimens patient . - Determine relapse patient treat regimen receive involved-field radiotherapy . OUTLINE : This randomize ( randomize part study complete 6/2005 ) , open-label , multicenter study . Patients stratify accord participate center , value serum lactic dehydrogenase ( great upper limit normal [ ULN ] v great ULN ) , bulky disease present ( vs yes ) , stage ( I II v III IV ) , general ECOG status patient ( 0 1 v 2 ) , age ( 61 70 vs 71-80 ) . Patients randomize 1 4 treatment arm . Patients CD20-negative lymphoma randomize arm I II . - Prephase treatment : Patients receive vincristine IV day -6 prednisone day -6 day 0 initiating CHOP chemotherapy . - Arm I ( close accrual 7/25/2005 ) : Patients receive standard CHOP chemotherapy comprise cyclophosphamide IV , doxorubicin IV , vincristine IV day 1 oral prednisone day 1-5 . Patients also receive filgrastim ( G-CSF ) subcutaneously daily day 6-12 CHOP course . Treatment repeat every 2 week 6 course . - Arm II ( close accrual 7/25/2005 ) : Patients receive standard CHOP chemotherapy G-CSF arm I total 8 course . - Arm III : Patients receive standard CHOP chemotherapy G-CSF arm I . Patients also receive rituximab IV CHOP every 2 week total 8 course . - Arm IV ( close accrual 7/25/2005 ) : Patients receive standard CHOP chemotherapy G-CSF arm II . Patients also receive rituximab IV CHOP every 2 week total 8 course . In arm , treatment continue absence disease progression unacceptable toxicity . Beginning 3-6 week completion last chemotherapy course , complete recovery bone marrow , complete remision mucositis , patient sit initial bulky disease extranodal involvement undergo radiotherapy 5 time week 4 week . Patients follow every 3 month 2 year , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : Approximately 1580 patient accrue study within 5 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm aggressive nonHodgkin 's lymphoma ( NHL ) excisional biopsy lymph node extensive biopsy extranodal involvement ( lymph node involvement ) CD20^+ Bcell lymphoma CD20^ Bcell Tcell lymphoma allow Bcell NHL include follow : Stage III follicular lymphoma Stage III follicular lymphoma diffuse Bcell lymphoma Lymphoblastic precursor Bcell lymphoma Diffuse large cell Bcell lymphoma Centroblastic Immunoblastic Plasmablastic Anaplastic large cell Tcellrich Bcell lymphoma Primary effusion lymphoma Intravasal Bcell lymphoma Primary mediastinal Bcell lymphoma Mantle zone lymphoma , blastoid Burkitt 's lymphoma Burkittlike lymphoma Aggressive marginal zone lymphoma ( monocytoid ) Tcell NHL include follow : Lymphoblastic precursor Tcell lymphoma Peripheral Tcell lymphoma ( PTCL ) otherwise specify ( NOS ) Lennert 's lymphoma Tzone lymphoma Tcell lymphoma angioimmunoblastic lymphadenopathy dysproteinemia ( AILD ) type Anaplastic large cell lymphoma ALK^+ ALK^ Extranodal NK/Tcell lymphoma , nasal type Intestinal T/NKcell lymphoma ( without enteropathy ) Hepatosplenic gammadelta lymphoma Subcutaneous panniculitislike PTCL Aggressive T/NK PTCL Anaplastic largecell NHL , NOS Bone marrow involvement 25 % No lymphoma clearly restrict CNS originate gastrointestinal tract PATIENT CHARACTERISTICS : Age 61 80 Performance status ECOG 02 OR Karnofsky 60100 % Life expectancy Not specify Hematopoietic WBC least 2,500/mm^3 Platelet count least 100,000/mm^3 Hepatic Bilirubin great 2 time upper limit normal ( ULN ) No active hepatitis infection Renal Creatinine great 2 time ULN Cardiovascular No Canadian Cardiovascular Society class III IV angina pectoris No New York Heart Association class III IV cardiac failure Ejection fraction least 50 % Fractional shortening least 25 % echocardiography nuclear medicine examination Pulmonary FEV1 least 50 % Diffusion capacity least 50 % Other No uncontrolled diabetes mellitus No know hypersensitivity study medication No concurrent malignancy HIV negative PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy No prior chemotherapy Endocrine therapy Not specify Radiotherapy No prior radiotherapy Surgery Not specify Other Must already initiate lymphoma therapy ( except prephase treatment specify study ) No concurrent lymphoma therapy No concurrent participation another treatment study</criteria>
	<gender>All</gender>
	<minimum_age>61 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2007</verification_date>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>angioimmunoblastic T-cell lymphoma</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage I adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage II adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage III adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
	<keyword>contiguous stage II adult lymphoblastic lymphoma</keyword>
	<keyword>noncontiguous stage II adult lymphoblastic lymphoma</keyword>
	<keyword>stage I adult lymphoblastic lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>stage I adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>contiguous stage II mantle cell lymphoma</keyword>
	<keyword>noncontiguous stage II mantle cell lymphoma</keyword>
	<keyword>stage I mantle cell lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>contiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>stage I adult Burkitt lymphoma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>contiguous stage II marginal zone lymphoma</keyword>
	<keyword>noncontiguous stage II marginal zone lymphoma</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>stage I marginal zone lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
</DOC>